868551-50-2

Usage

Uses

Used in Medicinal Chemistry:
1H-Pyrrolo[2,3-c]pyridine-5-carboxylic acid, 2,3-dibromo-1-[(4-fluorophenyl)methyl]-4-hydroxy-, methyl ester is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups allow for the development of new drugs with specific targeting and therapeutic properties.
Used in Drug Development:
In the pharmaceutical industry, 1H-Pyrrolo[2,3-c]pyridine-5-carboxylic acid, 2,3-dibromo-1-[(4-fluorophenyl)methyl]-4-hydroxy-, methyl ester serves as a building block for designing and optimizing drug candidates. Its potential biological activity and the ability to modify its structure through chemical synthesis make it a valuable asset in the discovery and development of novel therapeutic agents.
Used in Chemical Research:
1H-Pyrrolo[2,3-c]pyridine-5-carboxylic acid, 2,3-dibromo-1-[(4-fluorophenyl)methyl]-4-hydroxy-, methyl ester is utilized in academic and industrial research settings to study the effects of its unique structure and functional groups on biological systems. This research can lead to a better understanding of its potential applications and the development of new strategies for drug design and synthesis.

Upstream product

• 868551-49-9 ethyl 4,5-dibromo-1-(4-fluorobenzyl)-2-({(2-methoxy-2-oxoethyl)[(4-methylphenyl)sulfonyl]amino}methyl)-1H-pyrrole-3-carboxylate 
• 459-46-1 4-Fluorobenzyl bromide 
• 868551-48-8 ethyl 4,5-dibromo-2-(bromomethyl)-1-(4-fluorobenzyl)-1H-pyrrole-3-carboxylate 
• 868551-47-7 ethyl 1-(4-fluorobenzyl)-2-methyl-1H-pyrrole-3-carboxylate 
• 936-12-9 2-methyl-1H-pyrrole-3-carboxylic acid ethyl ester 

Downstream Products

• 868551-51-3 methyl 1-(4-fluorobenzyl)-4-hydroxy-1H-pyrrolo[2,3-c]pyridine-5-carboxylate 
• 1293387-89-9 (Z)-methyl 4-(2-ethoxyvinyl)-1-(4-fluorobenzyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylate 
• 1293388-12-1 1-[(2-pyridinylmethoxy)methyl]-3-(4-fluorobenzyl)-7-{[2-(trimethylsilyl)ethoxy]methoxy}-3,7,8,9-tetrahydro-6H-pyrrolo[2,3-c][1,7]naphthyridin-6-one 
• 1293387-93-5 1-[[2-(2-pyridinyl)ethoxy]methyl]-3-(4-fluorobenzyl)-7-{[2-(trimethylsilyl)ethoxy]methoxy}-3,7,8,9-tetrahydro-6H-pyrrolo[2,3-c][1,7]naphthyridin-6-one 
• 868551-52-4 methyl 1-(4-fluorobenzyl)-4-(trifluoromethylsulfonyloxy)-1H-pyrrolo[2,3-c]pyridine-5-carboxylate 
• 1293388-10-9 1-[(3,3-difluoropyrrolidin-1-yl)methyl]-3-(4-fluorobenzyl)-7-{[2-(trimethylsilyl)ethoxy]methoxy}-3,7,8,9-tetrahydro-6H-pyrrolo[2,3-c][1,7]naphthyridin-6-one 
• 1293388-09-6 1-{[(2-methoxyethyl)(methyl)amino]methyl}-3-(4-fluorobenzyl)-7-{[2-(trimethylsilyl)ethoxy]methoxy}-3,7,8,9-tetrahydro-6H-pyrrolo-[2,3-c][1,7]naphthyridin-6-one 
• 934621-58-6 3-(4-fluorobenzyl)-1-bromo-7-((2-(trimethylsilyl)ethoxy)methoxy)-8,9-dihydro-3H-pyrrolo[2,3-c][1,7]naphthyridin-6(7H)-one 
• 1161880-19-8 3-(4-fluorobenzyl)-1-iodo-7-{[2-(trimethylsilyl)ethoxy]methoxy}-8,9-dihydro-3H-pyrrolo[2,3-c][1,7]naphthyridin-6(7H)-one 

Relevant academic research and scientific papers

Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors

Figure Presented. HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication, and HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Recently, we reported the synthesis of orally bioavailable azaindole hydroxamic acids that were potent inhibitors of the HIV-1 IN enzyme. Here we disclose the design and synthesis of novel tricyclic N-hydroxy-dihydronaphthyridinones as potent, orally bioavailable HIV-1 integrase inhibitors displaying excellent ligand and lipophilic efficiencies.

INHIBITORS OF THE HIV INTEGRASE ENZYME

The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions comprisingm compounds of formula (I), and their methods of use in treating HIV-infected mammals.

INHIBITORS OF THE HIV INTEGRASE ENZYME

The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.

INHIBITORS OF THE HIV INTEGRASE ENZYME

The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.